ASTELLAS PHARMA UNSP.ADR Cash Flow Quality Index
ASTELLAS PHARMA UNSP.ADR cash flow quality index. ASTELLAS PHARMA UNSP.ADR (YPHA) has a Cash Flow Quality Index of 0.61x as of March 2025. Operating cash flow of €194.51 Billion is below net income of €319.72 Billion, suggesting accrual-heavy earnings not yet converted to cash. See how financially flexible is ASTELLAS PHARMA UNSP.ADR to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of ASTELLAS PHARMA UNSP.ADR (2022–2025)
Cash flow quality index of ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. Historical Cash Flow Quality Index for ASTELLAS PHARMA UNSP.ADR across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore ASTELLAS PHARMA UNSP.ADR debt service capacity to assess how comfortably operating cash covers total debt obligations.
ASTELLAS PHARMA UNSP.ADR Cash Flow Quality Index by Year (2022–2025)
ASTELLAS PHARMA UNSP.ADR cash flow quality index by year from 2022 to 2025. Year-by-year earnings quality comparison for ASTELLAS PHARMA UNSP.ADR. For the full cash flow conversion analysis, see how efficiently does ASTELLAS PHARMA UNSP.ADR generate cash.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.61x | €194.51 Billion | €319.72 Billion | ▲ +3.1% |
| 2024 | 0.59x | €172.47 Billion | €292.16 Billion | ▼ -82.2% |
| 2023 | 3.32x | €327.77 Billion | €98.71 Billion | ▲ +190.3% |
| 2022 | 1.14x | €257.44 Billion | €225.09 Billion | — |